Physician
Rheumatology
Dr. Alan J. Kivitz, MD
|
|
Give Review
Doctor Alan J. Kivitz, MD practices Rheumatology. He studied medicine at Albany Medical College. He received awards:"Fellow (FACP)", "Fellow (FACR)" and "Fellow". Alan J. Kivitz is a published physician as well. He has 62 publications published. The latest was: Apremilast in patients with active rheumatoid arthritis: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. He accepts Medicare.
Publications
- Sarilumab plus methotrexate in patients with active rheumatoid Arthritis and inadequate response to methotrexate: Results of a phase III study.
- Apremilast in patients with active rheumatoid Arthritis: A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
- Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid Arthritis.
- A Double-Blind, Placebo-Controlled, Randomized, 12-Week, Dose-Ranging Study of VX-509 (Decernotinib), an Oral Selective Janus Kinase 3 (JAK3) Inhibitor, as Monotherapy...
- Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study.
- Nearly Pain-Free Self-administration of Subcutaneous Methotrexate With an Autoinjector: Results of a Phase 2 Clinical Trial in Patients With Rheumatoid Arthritis Who H...
- Response to H Zeidler's comments on the CONCERTO study.
- Long-term safety and effectiveness of tanezumab as treatment for Chronic low back pain.
- Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of Pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthr...
- Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid Arthritis.
- Efficacy and safety of tanezumab versus naproxen in the treatment of Chronic low back pain.
- Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid Arthritis.
- Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers.
- A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoArthritis of the knee.
- Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid Arthritis.
- Abatacept in the treatment of patients with psoriatic Arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
- Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
- Long-term safety and efficacy of abatacept in children with juvenile idiopathic Arthritis.
- A walking model to assess the onset of analgesia in osteoArthritis knee pain.
- Efficacy and safety of naproxcinod in the treatment of patients with osteoArthritis of the knee: a 13-week prospective, randomized, multicenter study.
- Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene:...
- Epitope-specific immunotherapy of rheumatoid Arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules ass...
- Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid Arthritis: a randomized trial.
- Adalimumab effectiveness for the treatment of Ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
- Intraarticular injection of anakinra in osteoArthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study.
- Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal Osteoporosis.
- Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoArthritis-related knee pain: post hoc analysis of a 12 week, prospecti...
- Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with Rheumatoid arthriti...
- Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving Chronic glucocorticoid therapy.
- Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic Syndromes: results from two sequential placebo-controlled studies.
- Efficacy and safety of up to 192 weeks of etanercept therapy in patients with Ankylosing spondylitis.
- Improved health-related quality of life for patients with active rheumatoid Arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinic...
- A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic Arthritis.
- A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid Arthritis and concomitant comorbid diseases.
- Safety and efficacy of adalimumab in treatment of patients with psoriatic Arthritis who had failed disease modifying antirheumatic drug therapy.
- HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab.
- Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid Arthritis receiving adalimumab.
- Clinical assessment of Pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monocl...
- Efficacy and safety of adalimumab in patients with Ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
- Continued inhibition of radiographic progression in patients with psoriatic Arthritis following 2 years of treatment with etanercept.
- A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo i...
- Denosumab in postmenopausal women with low bone mineral density.
- A comparison of valdecoxib and naproxen in the treatment of rheumatoid Arthritis symptoms.
- Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of OsteoArthritis of the knee.
- Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporo...
- Sustained durability and tolerability of etanercept in Ankylosing spondylitis for 96 weeks.
- A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumato...
- The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoArthritis, and type...
- A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active Rheumatoid arthr...
- Pain management in osteoArthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
- Etanercept treatment of psoriatic Arthritis: safety, efficacy, and effect on disease progression.
- Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid Arthritis.
- Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoArthritis of the knee: a randomized controlled trial.
- Recombinant human tumor necrosis factor receptor (etanercept) for treating Ankylosing spondylitis: a randomized, controlled trial.
- Management of postmenopausal Osteoporosis.
- A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects.
- Allele and antigen-specific treatment of rheumatoid Arthritis: a double blind, placebo controlled phase 1 trial.
- Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoArthritis.
- Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoArthritis of the hip.
- Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid Arthritis: a randomized controlled trial.
- Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoArthritis patients at high risk for developing nonsteroidal anti-inflammatory dr...
Schools
Albany Medical College
North Shore University Hospital
Albany Medical Center Hospital
Albany Med College
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
- Trigger Point Injection
- View All
Conditions Treated
- Ankylosing Spondylitis
- Arthritis
- Bursitis
- Carpal Tunnel Syndrome
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- Fellow (FACP)
- Fellow (FACR)
- Fellow
Education
-
Albany Medical Center -
North Shore-Long Island Jewish Health System -
Albany Medical College
Hospital
-
UPMC Altoona
Drug Facts
| NPI NUMBER | 1447259023 | |
| NPPES Provider LastName | KIVITZ | |
| NPPES Provider FirstName | ALAN | |
| NPPES Provider ZIPCode | 166358445 | |
| NPPES Provider State | PA | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 6120.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 406.0 | |
| Percent Opioid Claims | 6.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447259023 |
| Last Name Of The Provider | KIVITZ |
| First Name Of The Provider | ALAN |
| View All |
Similar Doctors
|
|
Dr. Frederick T. Murphy, MD |
|
|
Dr. Veronica K. Newsome, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lori A. Lavelle, DO |
|
|
Dr. Marianne L. Shaw, MD
This Doctor is OpenDoctor Recommended.
|